文献速递胸部肿瘤

低剂量CT在高危人群中进行肺癌筛查(SUMMIT):一项前瞻性纵向队列研究

Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
PubMed 文献 · Lancet Oncol · 2025-03-25

SUMMIT研究在伦敦329家基层诊所招募12773名高危吸烟者,行低剂量CT肺癌筛查。基线轮检出肺癌261例(2.0%),其中79.3%为I-II期,77.0%以手术为主要治疗。12个月时筛查方案对肺癌检出的敏感性为97.0%,特异性为95.2%,假阳性率4.8%。

要点

  • 高危人群低剂量CT筛查肺癌检出率2.0%,I-II期占79.3%。
  • 12个月敏感性97.0%,特异性95.2%,假阳性率4.8%。
  • 手术切除中良性病变占11.6%,术后90天内死亡1例(0.4%)。

核心结论

  • 大规模肺癌筛查有效,并可高效地服务于种族和社会经济多样化的人群。

研究设计与样本

  • 前瞻性纵向队列研究,从伦敦329家基层诊所招募55-77岁既往20年内有吸烟记录者,邀请参加肺部健康检查。
  • 符合2013年美国预防服务工作组标准(过去15年内当前或既往吸烟,吸烟史至少30包年)或PLCO 2012模型6年风险≥1.3%,且未因活动性癌症接受治疗(辅助激素治疗除外)者入组。
  • 入组者接受非增强薄准直低剂量CT筛查,本分析报告基线轮低剂量CT筛查结果,主要终点为评估肺癌筛查服务性能的相关指标,按参与者水平用描述性频率分析。
  • 研究注册号ClinicalTrials.gov NCT03934866。

主要发现

  • 2019年4月8日至2021年5月14日共招募并分析12773名参与者,其中男性7353例(57.6%),女性5420例(42.4%),白人10665例(83.5%)。
  • 261例(2.0%)参与者诊断为肺癌,包括163例(1.3%)筛查检出肺癌和98例(0.8%)延迟筛查检出肺癌(即经过3个月或6个月结节随访CT后检出)。
  • 276例(2.2%)参与者在基线筛查阳性后诊断为任何胸腔内恶性肿瘤。
  • 261例筛查检出的流行肺癌中,207例(79.3%)诊断时为I期或II期,201例(77.0%)以手术切除为主要治疗方式。
  • 包括同一参与者多次切除(如同时性原发灶)的情况,241次手术切除中28次(11.6%)为良性,术后90天内有1例(0.4%)死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose CT screening reduces lung cancer mortality. In advance of planned national lung cancer screening programmes, research is needed to inform policies regarding implementation. We aimed to assess the implementation of low-dose CT for lung cancer screening in a high-risk population and to validate a multicancer early detection blood test. METHODS: In this prospective, longitudinal cohort study, individuals aged 55-77 years recorded as current smokers in their primary care records at any point within the past 20 years were identified from 329 primary care practices in London (UK) and invited for a lung health check via postal letter. Individuals meeting the 2013 United States Preventive Services Taskforce criteria (current or former smokers within the past 15 years with at least 30 pack-year smoking histories) or having a Prostate, Lung, Colorectal and Ovarian 2012 model 6-year risk of 1·3% or greater, and not currently receiving treatment for an active cancer (except adjuvant hormonal therapy), were eligible for the study. These individuals underwent lung cancer screening via non-contrast, thin collimation low-dose CT. In this analysis, we report the results of the baseline round of low-dose CT screening. Key primary endpoints were those associated with examining the performance of a lung cancer screening service. Outcome measures were analysed on a per-participant level using descriptive frequencies. The study was registered with ClinicalTrials.gov, NCT03934866. FINDINGS: Between April 8, 2019, and May 14, 2021, 12 773 participants were recruited and analysed. 7353 (57·6%) of 12 773 participants were male and 5420 (42·4%) were female, and 10 665 (83·5%) participants were White. 261 (2·0%) of 12 773 participants were diagnosed with lung cancer (including 163 [1·3%] participants with screen-detected lung cancer and 98 [0·8%] with delayed screen-detected lung cancer [ie, after a 3-month or 6-month nodule follow-up CT]) and 276 (2·2%) participants were diagnosed with any intrathoracic malignancy after a positive baseline screen. 207 (79·3%) of 261 individuals with prevalent screen-detected lung cancer were diagnosed at stage I or II and surgical resection was the primary treatment modality in 201 (77·0%) of 261 individuals. Including cases where multiple resections were done in the same participant (eg, for synchronous primaries), 28 (11·6%) of 241 surgical resections were benign, and there was one (0·4%) death within 90 days of surgery. At 12 months, the episode sensitivity of our low-dose CT screening protocol for detecting lung cancer was 97·0% (95% CI 95·0-99·1; 261 of 269 participants). The specificity was 95·2% (94·8-95·6; 11 905 of 12 504 participants), with a false-positive rate of 4·8% (4·4-5·2). INTERPRETATION: Large-scale lung cancer screening is effective and can be delivered efficiently to an ethnically and socioeconomically diverse population. FUNDING: GRAIL.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bhamani A, Creamer A, Verghese P, et al. Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study. Lancet Oncol. 2025. PMID: 40154514. doi:10.1016/S1470-2045(25)00082-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。